{"id":"W4390271738","doi":"10.1111/hiv.13593","title":"Twelve‐month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with <scp>HIV</scp>: Real‐world insights from <scp>BICSTaR</scp> cohorts","year":2023,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"ca_institutions":"Maple Leaf Medical Clinic","funders":"Merck Canada; Moderna; Novavax; Gilead Sciences; Pfizer; Mylan; ViiV Healthcare; Eli Lilly and Company","keywords":"Emtricitabine; Medicine; Tenofovir alafenamide; Internal medicine; Regimen; Tolerability; Population; Adverse effect; Clinical endpoint; Human immunodeficiency virus (HIV); Viral load; Clinical trial; Immunology; Antiretroviral therapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004721778,0.0004285429,0.0008442163,0.0004334166,0.0004328117,0.000912053,0.0003424142,0.0005137834,0.0016711],"category_scores_gemma":[0.004367922,0.0002697609,0.001673806,0.0007338107,0.0003034073,0.00050416,0.0006344731,0.0007414059,0.0002756418],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006400427,"about_ca_system_score_gemma":0.0006415668,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002329498,"about_ca_topic_score_gemma":0.003303736,"domain_scores_codex":[0.9984462,0.0006831682,0.0002348236,0.000229267,0.0002559178,0.0001506709],"domain_scores_gemma":[0.9960364,0.0008943669,0.001867722,0.0003079436,0.0004317194,0.0004619331],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1596039,0.001897574,0.7759854,0.001175143,0.006031104,0.0001586084,0.0006548469,0.0009929371,0.001389281,0.00007415329,0.001729244,0.05030771],"study_design_scores_gemma":[0.005983588,0.03220518,0.9532844,0.0002457567,0.004290123,0.0003393282,0.0003193752,0.0007114162,0.0007901108,0.0001036133,0.001680604,0.00004655845],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957949,0.001692363,0.00009768501,0.00004779511,0.00001332688,0.0000929009,0.001726496,0.00000585991,0.0005287531],"genre_scores_gemma":[0.9968177,0.0004336952,0.0001603757,0.00005003497,0.00001497599,0.00009037423,0.002193981,0.000002911487,0.0002358352],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004721778,"threshold_uncertainty_score":0.02497143,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007947414303070334,"score_gpt":0.2350739832618673,"score_spread":0.227126568958797,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}